Mast Group has launched the MAST CARBA PAcE for rapid carbapenemase detection in Pseudomonas, Acinetobacter and Enterobacterales.
An increase in antimicrobial resistance is one of the most urgent global challenges facing the field of healthcare. Carbapenem-resistant bacteria are an emerging cause of healthcare-associated infection and are particularly concerning due to the high level of antimicrobial resistance coupled with the ability for widespread transmission.
Accordingly, it is important to detect carriers quickly to prevent and control spread and also to aid antimicrobial stewardship. Mast Group has developed a colourimetric test that rapidly detects carbapenemase-producing Pseudomonas spp., Acinetobacter spp. and Enterobacterales using a chromogenic cephalosporin analogue.
MAST CARBA PAcE is a simple, cost-effective solution providing fast results within 10 minutes, conveniently containing 48 tests per kit, making it ideal for screening purposes, and supporting effective infection prevention and control. With no special equipment required, the test can be easily adaptable to any microbiology laboratory.
